Bosch Introduces New HQL Sterilization Tunnel Series
![](/46/pdcnewsitem/03/31/39/x5Ek94AnWNxzlTg.jpg)
At Interpack 2014, Bosch Packaging Technology, a leading supplier of process and packaging technology, presents the new 6000, 7000 and 8000 series of the HQL drying and sterilization tunnel. This new generation of tunnels is an energy-saving and especially flexible advancement of the proven HQL series for sterilizing and depyrogenizing pre-cleaned ampoules, injection and infusion bottles, as well as cartridges and syringes.
The modular design of the HQL series ensures a customer-specific tunnel arrangement. Each sterilizing and cooling module contains the entire technology for the respective process step. “The modules can now be variably put together. This allows the new series to be flexibly integrated into different line concepts,” Matthias Angelmaier, product manager at Bosch Packaging Technology, explains. In addition, the new design facilitates access to critical areas such as HEPA filters, which can be easily replaced, thus simplifying maintenance of the tunnels.
Savings in Energy and Space
Pharmaceutical manufacturers profit from the increased energy efficiency of the new HQL series. In contrast to most sterilization tunnels, the new series requires less energy for electrical heating and ventilation due to an optimized airflow and measures for heat recovery. A flexible pressure zone concept ensures increased process safety by adapting tunnel pressures in the different zones to customers' requirements. The new tunnels are further characterized by a reduced overall tunnel size, making them shorter and more space-saving than the previous series.
Three Standardized Conveyor Belt Sizes
The new tunnels are available in three standardized bandwidths of 600 respectively 800 mm for the HQL 6000 and 7000 and 1 200 mm for the HQL 8000, which is on display at Interpack. With its different sizes, the drying and sterilization tunnel can be flexibly adapted to different requirements.
“Based on the physical properties of our customers' packaging material we calculate, which tunnel modules are adequate for their processes,” Angelmaier explains. This subsequently facilitates safe process validation and documentation. “The HQL 8000, for instance, with its broad conveyor belt and several sterilizing and cooling modules is suited for large glass containers and downstream filling machines with high output.” The horizontal transport belt made of a stainless steel wire mesh makes sure all freestanding and non-freestanding containers are transported through the HQL tunnel gently and without abrasion.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance